Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03127956 · ClinicalTrials.gov registry record · Phase 3
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
A Phase 3 study of Acne Vulgaris, sponsored by Dermira.
- Completed
- Registry status
- Phase 3
- Development phase
- 748
- Enrollment target
- 20
- Study locations
NCT03127956 is a Phase 3 study of Acne Vulgaris that has completed, run by Dermira. The registered enrollment target is 748 participants, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (183% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT03127956, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Dermira.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 748 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the long-term safety of Olumacostat Glasaretil gel, 5.0% in patients with acne vulgaris
Conditions Studied
Interventions
- DRUG Olumacostat Glasaretil Gel, 5.0%
Study Locations (20)
California
- Anaheim Clinical Trials - Anaheim
- Center for Dermatology Clinical Research, Inc. - Fremont
- Advanced Skincare Surgery & MedCenter - Fullerton
- Dermatology Research Associates - Los Angeles
- Northern California Research - Sacramento
- Rady Children's Hospital UCSD Pediatric and Adolescent Derm - San Diego
- TCR Medical Corporation - San Diego
- University Clinical Trials Inc. - San Diego
- Radiant Research, Inc. - Santa Rosa
Florida
- Center for Clincial and Cosmetic Research - Aventura
- Florida Academic Centers Research & Education - Coral Gables
- Aby's New Generation Research Inc. - Hialeah
Arizona
- Advanced Research Associates - Glendale
- Alliance Dermatology & MOHS Center - Phoenix
Arkansas
- Dermatology Trial Associates - Bryant
- Northwest Arkansas Clinical Trials Center - Rogers
Colorado
- Alpine Clinical Research Center - Boulder
- Horizons Clinical Research Center, LLC - Denver
Alabama
- Avant Research Associates, LLC - Guntersville
Connecticut
- Dermatology Physicians of CT - Shelton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 748 participants |
| Start Date | 2017-03-21 |
| Est. Completion | 2018-04-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03127956
The ClinicalTrials.gov registry entry for NCT03127956 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 748 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (183% higher). The listed sponsor is Dermira, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Olumacostat Glasaretil Gel, 5.0% is the first listed.
NCT03127956 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03127956 about?
NCT03127956 is a clinical study titled "A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris". The objective of this study is to assess the long-term safety of Olumacostat Glasaretil gel, 5.0% in patients with acne vulgaris
What is the current status of trial NCT03127956?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 748 participants. The study started on 2017-03-21. Estimated completion is 2018-04-27.
What conditions does trial NCT03127956 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT03127956?
The interventions under investigation include: Olumacostat Glasaretil Gel, 5.0% (DRUG).
Who is sponsoring clinical trial NCT03127956?
This trial is sponsored by Dermira, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03127956 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
COMPLETED · Phase 3
-
A Study of S6G5T3 in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
P3 Long Term Safety Study of Once Daily SB204 in Acne
COMPLETED · Phase 3
-
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
COMPLETED · Phase 3
-
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.